An investigation of adherence to best practice guidelines for autism diagnosis in New Zealand / L. J. TAYLOR in Autism, 25-7 (October 2021)  

Public ISBD [article]  inAutism > 25-7 (October 2021) . - p.2087-2100 Titre : An investigation of adherence to best practice guidelines for autism diagnosis in New Zealand Type de document : Texte imprimé et/ou numérique Auteurs : L. J. TAYLOR, Auteur ; Matthew J. F. EGGLESTON, Auteur ; H. THABREW, Auteur ; L. VAN DER MEER, Auteur ; H. WADDINGTON, Auteur ; Andrew J. O. WHITEHOUSE, Auteur ; K. EVANS, Auteur Article en page(s) : p.2087-2100 Langues : Anglais (eng) Mots-clés : Adolescent  Adult  Autism Spectrum Disorder  Autistic Disorder/diagnosis  Child  Humans  New Zealand  clinical guidelines  diagnosis  implementation Index. décimale : PER Périodiques Résumé : Many clinicians in New Zealand do not follow guidelines for best practice in autism diagnosis. In this study, we investigated the processes that health professionals in New Zealand follow when diagnosing autistic children and adults. We asked 117 health professionals from a range of services and regions in New Zealand, how they identify and diagnose autism. We found that there are differences in the way that clinicians in New Zealand diagnose autism. We identified areas in which autism diagnosis in New Zealand could be improved, for example, by establishing more services to diagnose autism in adolescents and adults, and providing more consistent support after a person is diagnosed with autism. These findings will help to improve autism diagnosis in New Zealand. En ligne : http://dx.doi.org/10.1177/13623613211015757 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=451 [article] An investigation of adherence to best practice guidelines for autism diagnosis in New Zealand [Texte imprimé et/ou numérique] / L. J. TAYLOR, Auteur ; Matthew J. F. EGGLESTON, Auteur ; H. THABREW, Auteur ; L. VAN DER MEER, Auteur ; H. WADDINGTON, Auteur ; Andrew J. O. WHITEHOUSE, Auteur ; K. EVANS, Auteur . - p.2087-2100. Langues : Anglais (eng) in Autism > 25-7 (October 2021) . - p.2087-2100 Mots-clés : Adolescent  Adult  Autism Spectrum Disorder  Autistic Disorder/diagnosis  Child  Humans  New Zealand  clinical guidelines  diagnosis  implementation Index. décimale : PER Périodiques Résumé : Many clinicians in New Zealand do not follow guidelines for best practice in autism diagnosis. In this study, we investigated the processes that health professionals in New Zealand follow when diagnosing autistic children and adults. We asked 117 health professionals from a range of services and regions in New Zealand, how they identify and diagnose autism. We found that there are differences in the way that clinicians in New Zealand diagnose autism. We identified areas in which autism diagnosis in New Zealand could be improved, for example, by establishing more services to diagnose autism in adolescents and adults, and providing more consistent support after a person is diagnosed with autism. These findings will help to improve autism diagnosis in New Zealand. En ligne : http://dx.doi.org/10.1177/13623613211015757 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=451

An investigation of adherence to best practice guidelines for autism diagnosis in New Zealand / Lauren J. TAYLOR in Autism, 26-7 (October 2022)  

Public ISBD [article]  inAutism > 26-7 (October 2022) . - p.2087-2100 Titre : An investigation of adherence to best practice guidelines for autism diagnosis in New Zealand Type de document : Texte imprimé et/ou numérique Auteurs : Lauren J. TAYLOR, Auteur ; Matthew J. F. EGGLESTON, Auteur ; Hiran THABREW, Auteur ; Larah VAN DER MEER, Auteur ; Hannah WADDINGTON, Auteur ; Andrew J. O. WHITEHOUSE, Auteur ; Kiah EVANS, Auteur Article en page(s) : p.2087-2100 Langues : Anglais (eng) Mots-clés : Adolescent  Adult  Autism Spectrum Disorder  Autistic Disorder/diagnosis  Child  Humans  New Zealand  autism spectrum disorder  clinical guidelines  diagnosis  implementation Index. décimale : PER Périodiques Résumé : Many clinicians in New Zealand do not follow guidelines for best practice in autism diagnosis. In this study, we investigated the processes that health professionals in New Zealand follow when diagnosing autistic children and adults. We asked 117 health professionals from a range of services and regions in New Zealand, how they identify and diagnose autism. We found that there are differences in the way that clinicians in New Zealand diagnose autism. We identified areas in which autism diagnosis in New Zealand could be improved, for example, by establishing more services to diagnose autism in adolescents and adults, and providing more consistent support after a person is diagnosed with autism. These findings will help to improve autism diagnosis in New Zealand. En ligne : http://dx.doi.org/10.1177/13623613211015757 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=484 [article] An investigation of adherence to best practice guidelines for autism diagnosis in New Zealand [Texte imprimé et/ou numérique] / Lauren J. TAYLOR, Auteur ; Matthew J. F. EGGLESTON, Auteur ; Hiran THABREW, Auteur ; Larah VAN DER MEER, Auteur ; Hannah WADDINGTON, Auteur ; Andrew J. O. WHITEHOUSE, Auteur ; Kiah EVANS, Auteur . - p.2087-2100. Langues : Anglais (eng) in Autism > 26-7 (October 2022) . - p.2087-2100 Mots-clés : Adolescent  Adult  Autism Spectrum Disorder  Autistic Disorder/diagnosis  Child  Humans  New Zealand  autism spectrum disorder  clinical guidelines  diagnosis  implementation Index. décimale : PER Périodiques Résumé : Many clinicians in New Zealand do not follow guidelines for best practice in autism diagnosis. In this study, we investigated the processes that health professionals in New Zealand follow when diagnosing autistic children and adults. We asked 117 health professionals from a range of services and regions in New Zealand, how they identify and diagnose autism. We found that there are differences in the way that clinicians in New Zealand diagnose autism. We identified areas in which autism diagnosis in New Zealand could be improved, for example, by establishing more services to diagnose autism in adolescents and adults, and providing more consistent support after a person is diagnosed with autism. These findings will help to improve autism diagnosis in New Zealand. En ligne : http://dx.doi.org/10.1177/13623613211015757 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=484

Consensus or chaos: Survey of prescribing practices of New Zealand child and adolescent psychiatrists for children and adolescents with autism spectrum disorder / Hiran THABREW in Research in Autism Spectrum Disorders, 74 (June 2020)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 74 (June 2020) . - p.101553 Titre : Consensus or chaos: Survey of prescribing practices of New Zealand child and adolescent psychiatrists for children and adolescents with autism spectrum disorder Type de document : Texte imprimé et/ou numérique Auteurs : Hiran THABREW, Auteur ; Anisha VISWANATHAN, Auteur ; Matthew J. F. EGGLESTON, Auteur ; Stephanie MOOR, Auteur ; David CHINN, Auteur Article en page(s) : p.101553 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Autism  Children  Adolescents  Pharmacotherapy  Guidelines Index. décimale : PER Périodiques Résumé : Background There is limited national and international guidance on appropriate prescription of medications for children and adolescents with Autism Spectrum Disorder (ASD). In order to develop more detailed guidelines for prescribing for New Zealand children and young people with ASD, it is important to have some understanding of the nature of current prescribing and the circumstances that drive pharmacotherapy for children and young people with ASD. Method Seventy child and adolescent psychiatrists in New Zealand were electronically surveyed. Participants were asked to outline the four most common medications that they prescribed to address both core symptoms and comorbidities in children and young people with ASD. Additional questions included commonly used doses and durations of use, perceived effectiveness, adverse effects, level of confidence in prescribing and preferences for receiving up to date guidance about pharmacotherapy. Results Prescription by child and adolescent psychiatrists was most commonly undertaken for anxiety, sleep disturbance, ADHD, depression and restricted and repetitive behaviours (RRBs). The greatest difference in opinion regarding the value of medication related to the treatment of RRBs. The most commonly prescribed medications were fluoxetine, methylphenidate, melatonin, risperidone, quetiapine and clonidine. A range of non-pharmacological therapies were also described. Conclusions Although there appears to be general agreement between New Zealand child and adolescent psychiatrists regarding prescribing for children and young people with ASD, current clinical practice is not adequately informed by existing guidelines. Better dissemination of national guidelines incorporating both contemporary international evidence regarding medication efficacy and locally developed algorithms based on clinician consensus would be useful. En ligne : https://doi.org/10.1016/j.rasd.2020.101553 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=422 [article] Consensus or chaos: Survey of prescribing practices of New Zealand child and adolescent psychiatrists for children and adolescents with autism spectrum disorder [Texte imprimé et/ou numérique] / Hiran THABREW, Auteur ; Anisha VISWANATHAN, Auteur ; Matthew J. F. EGGLESTON, Auteur ; Stephanie MOOR, Auteur ; David CHINN, Auteur . - p.101553. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 74 (June 2020) . - p.101553 Mots-clés : Autism spectrum disorder  Autism  Children  Adolescents  Pharmacotherapy  Guidelines Index. décimale : PER Périodiques Résumé : Background There is limited national and international guidance on appropriate prescription of medications for children and adolescents with Autism Spectrum Disorder (ASD). In order to develop more detailed guidelines for prescribing for New Zealand children and young people with ASD, it is important to have some understanding of the nature of current prescribing and the circumstances that drive pharmacotherapy for children and young people with ASD. Method Seventy child and adolescent psychiatrists in New Zealand were electronically surveyed. Participants were asked to outline the four most common medications that they prescribed to address both core symptoms and comorbidities in children and young people with ASD. Additional questions included commonly used doses and durations of use, perceived effectiveness, adverse effects, level of confidence in prescribing and preferences for receiving up to date guidance about pharmacotherapy. Results Prescription by child and adolescent psychiatrists was most commonly undertaken for anxiety, sleep disturbance, ADHD, depression and restricted and repetitive behaviours (RRBs). The greatest difference in opinion regarding the value of medication related to the treatment of RRBs. The most commonly prescribed medications were fluoxetine, methylphenidate, melatonin, risperidone, quetiapine and clonidine. A range of non-pharmacological therapies were also described. Conclusions Although there appears to be general agreement between New Zealand child and adolescent psychiatrists regarding prescribing for children and young people with ASD, current clinical practice is not adequately informed by existing guidelines. Better dissemination of national guidelines incorporating both contemporary international evidence regarding medication efficacy and locally developed algorithms based on clinician consensus would be useful. En ligne : https://doi.org/10.1016/j.rasd.2020.101553 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=422

Melatonin dispensing and polypharmacy rates for New Zealand children with autism or attention deficit hyperactivity disorders: A nationwide pharmacoepidemiological study / Laurie K. MCLAY in Research in Autism Spectrum Disorders, 93 (May 2022)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 93 (May 2022) . - 101948 Titre : Melatonin dispensing and polypharmacy rates for New Zealand children with autism or attention deficit hyperactivity disorders: A nationwide pharmacoepidemiological study Type de document : Texte imprimé et/ou numérique Auteurs : Laurie K. MCLAY, Auteur ; Nicholas J. BOWDEN, Auteur ; Matthew J. F. EGGLESTON, Auteur ; Hiran THABREW, Auteur ; Rhiannon BRAUND, Auteur ; Philip J. SCHLUTER, Auteur Article en page(s) : 101948 Langues : Anglais (eng) Mots-clés : Autism  Attention deficit hyperactivity disorder  Melatonin  Sleep  Polypharmacy Index. décimale : PER Périodiques Résumé : Background Chronic insomnia is common in children with autism and Attention Deficit Hyperactivity Disorder (ADHD). Melatonin is often used to treat childhood insomnia. However, it may interact with other medications being used to manage other symptoms. This pharmacoepidemiological study examined the rates of general and psychotropic polypharmacy among children with autism and/or ADHD, stratified by melatonin dispensing. The impact of sociodemographic and child characteristics on such dispensing was also examined. Method Linked national health and pharmaceutical administrative data for children aged 0?18 years in 2019 was utilized. Overall and melatonin dispensing stratified polypharmacy rates were calculated. Ordinal logistic regression models were employed to compare groups and adjust for confounders. Results Data were acquired for 10,209 children with autism (18.5% were dispensed melatonin), 5970 with ADHD (22.3% were dispensed melatonin), 2064 with autism and ADHD (29.9% were dispensed melatonin), and 1156,296 without a diagnosis of autism or ADHD (a control group; 0.5% dispensed melatonin). Relative to controls, rates of melatonin dispensing and polypharmacy were higher in children with autism and ADHD, and highest among those with both conditions. Children dispensed melatonin experienced the greatest rates of polypharmacy, especially if they had both autism and ADHD. Conclusions Children with autism and ADHD experience significant medication burden and potentially adverse interactions between psychotropic and sleep-related medication, raising important questions regarding their clinical care. En ligne : https://doi.org/10.1016/j.rasd.2022.101948 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=475 [article] Melatonin dispensing and polypharmacy rates for New Zealand children with autism or attention deficit hyperactivity disorders: A nationwide pharmacoepidemiological study [Texte imprimé et/ou numérique] / Laurie K. MCLAY, Auteur ; Nicholas J. BOWDEN, Auteur ; Matthew J. F. EGGLESTON, Auteur ; Hiran THABREW, Auteur ; Rhiannon BRAUND, Auteur ; Philip J. SCHLUTER, Auteur . - 101948. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 93 (May 2022) . - 101948 Mots-clés : Autism  Attention deficit hyperactivity disorder  Melatonin  Sleep  Polypharmacy Index. décimale : PER Périodiques Résumé : Background Chronic insomnia is common in children with autism and Attention Deficit Hyperactivity Disorder (ADHD). Melatonin is often used to treat childhood insomnia. However, it may interact with other medications being used to manage other symptoms. This pharmacoepidemiological study examined the rates of general and psychotropic polypharmacy among children with autism and/or ADHD, stratified by melatonin dispensing. The impact of sociodemographic and child characteristics on such dispensing was also examined. Method Linked national health and pharmaceutical administrative data for children aged 0?18 years in 2019 was utilized. Overall and melatonin dispensing stratified polypharmacy rates were calculated. Ordinal logistic regression models were employed to compare groups and adjust for confounders. Results Data were acquired for 10,209 children with autism (18.5% were dispensed melatonin), 5970 with ADHD (22.3% were dispensed melatonin), 2064 with autism and ADHD (29.9% were dispensed melatonin), and 1156,296 without a diagnosis of autism or ADHD (a control group; 0.5% dispensed melatonin). Relative to controls, rates of melatonin dispensing and polypharmacy were higher in children with autism and ADHD, and highest among those with both conditions. Children dispensed melatonin experienced the greatest rates of polypharmacy, especially if they had both autism and ADHD. Conclusions Children with autism and ADHD experience significant medication burden and potentially adverse interactions between psychotropic and sleep-related medication, raising important questions regarding their clinical care. En ligne : https://doi.org/10.1016/j.rasd.2022.101948 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=475

Obtaining an autism spectrum disorder diagnosis and supports: New Zealand parents’ experiences / Matthew J. F. EGGLESTON in Research in Autism Spectrum Disorders, 62 (June 2019)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 62 (June 2019) . - p.18-25 Titre : Obtaining an autism spectrum disorder diagnosis and supports: New Zealand parents’ experiences Type de document : Texte imprimé et/ou numérique Auteurs : Matthew J. F. EGGLESTON, Auteur ; Hiran THABREW, Auteur ; Christopher M. A. FRAMPTON, Auteur ; Katherine H. F. EGGLESTON, Auteur ; Shannon C. HENNIG, Auteur Article en page(s) : p.18-25 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Parent  Satisfaction  Diagnosis  Supports  Survey Index. décimale : PER Périodiques Résumé : Background This study explored New Zealand parents’ experiences of obtaining an autism spectrum disorder (ASD) diagnosis for their child and aimed to identify factors that predicted parent satisfaction. Method Parents of ASD parent support groups were invited by email to participate in an anonymous online survey. Parents were asked to rate their satisfaction with a number of key aspects of the diagnostic process for ASD. Correlation analysis and ANOVA were utilized to explore possible associations between parent satisfaction and putative demographic and clinical factors and experiences. Multiple regression analysis was used to identify key predictor variables of parent satisfaction and stress. Results Parent (n?=?516) satisfaction with the diagnostic process for ASD was endorsed by 53.1%. The strongest predictor was satisfaction with the diagnostic assessment report, followed by higher levels of parent stress. Higher satisfaction was also predicted by spending less time on a wait-list for assessment, multi-disciplinary assessment and the absence of concurrent ADHD. Most parents found the diagnostic process stressful. Only 23% of parents were satisfied with post-diagnostic supports, and just 19% their coordination. Conclusions Just over half of New Zealand parents are satisfied with the diagnostic process for ASD, despite most finding the process stressful. Streamlining referral pathways, reducing assessment wait-times and increasing rates of multi-disciplinary team assessment may raise satisfaction rates further. Receiving a satisfactory diagnostic assessment report appears to be of particular importance to parents. The very low rate of satisfaction with post-diagnostic supports indicates that further development of these services is a priority for NZ. En ligne : https://doi.org/10.1016/j.rasd.2019.02.004 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=389 [article] Obtaining an autism spectrum disorder diagnosis and supports: New Zealand parents’ experiences [Texte imprimé et/ou numérique] / Matthew J. F. EGGLESTON, Auteur ; Hiran THABREW, Auteur ; Christopher M. A. FRAMPTON, Auteur ; Katherine H. F. EGGLESTON, Auteur ; Shannon C. HENNIG, Auteur . - p.18-25. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 62 (June 2019) . - p.18-25 Mots-clés : Autism spectrum disorder  Parent  Satisfaction  Diagnosis  Supports  Survey Index. décimale : PER Périodiques Résumé : Background This study explored New Zealand parents’ experiences of obtaining an autism spectrum disorder (ASD) diagnosis for their child and aimed to identify factors that predicted parent satisfaction. Method Parents of ASD parent support groups were invited by email to participate in an anonymous online survey. Parents were asked to rate their satisfaction with a number of key aspects of the diagnostic process for ASD. Correlation analysis and ANOVA were utilized to explore possible associations between parent satisfaction and putative demographic and clinical factors and experiences. Multiple regression analysis was used to identify key predictor variables of parent satisfaction and stress. Results Parent (n?=?516) satisfaction with the diagnostic process for ASD was endorsed by 53.1%. The strongest predictor was satisfaction with the diagnostic assessment report, followed by higher levels of parent stress. Higher satisfaction was also predicted by spending less time on a wait-list for assessment, multi-disciplinary assessment and the absence of concurrent ADHD. Most parents found the diagnostic process stressful. Only 23% of parents were satisfied with post-diagnostic supports, and just 19% their coordination. Conclusions Just over half of New Zealand parents are satisfied with the diagnostic process for ASD, despite most finding the process stressful. Streamlining referral pathways, reducing assessment wait-times and increasing rates of multi-disciplinary team assessment may raise satisfaction rates further. Receiving a satisfactory diagnostic assessment report appears to be of particular importance to parents. The very low rate of satisfaction with post-diagnostic supports indicates that further development of these services is a priority for NZ. En ligne : https://doi.org/10.1016/j.rasd.2019.02.004 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=389

A Survey of Autistic Adults from New Zealand on the Autism Diagnostic Process During Adolescence and Adulthood / K. EVANS in Journal of Autism and Developmental Disorders, 52-2 (February 2022)  

Permalink

Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorder / Marita BROADSTOCK in Autism, 11-4 (July 2007)  

Permalink

Vitamin?mineral treatment improves aggression and emotional regulation in children with ADHD: a fully blinded, randomized, placebo?controlled trial / Julia J. RUCKLIDGE in Journal of Child Psychology and Psychiatry, 59-3 (March 2018)  

Permalink

---

1 (1 - 8 / 8)